Academia and industry agreement on a feasibility tool for first-time-in-human clinical trial units
Moraga, Paloma (Hospital Universitario La Paz (Madrid))
Prieto, Paula (Hospital Universitario La Paz (Madrid))
Conradie, Almari (Global Alliance for TB Drug Development (TB Alliance))
Benhayoun, Majda (Global Alliance for TB Drug Development (TB Alliance))
Rousell, Vicki (GlaxoSmithKline)
Davy, Maria (GlaxoSmithKline)
Fuhr, Uwe (University of Cologne)
Antonijoan Arbós, Rosa Ma (Rosa María) (Institut d'Investigació Biomèdica Sant Pau)
Abad-Santos, Francisco (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas)
Portolés, Antonio (Universidad Complutense de Madrid)
Van Duinen, Jolanda (QPS Netherlands BV)
Carcas, Antonio J. (Instituto de Salud Carlos III)
Borobia, Alberto M. (Instituto de Salud Carlos III)
Universitat Autònoma de Barcelona

Date:	2023
Abstract:	First-time-in-human (FTIH) trials are designed to generate information on the safety, tolerability, as well as the pharmacokinetic and pharmacodynamics profile of new drugs. To ensure the safety of participants, these trials need to be conducted at specifically equipped phase I clinical trial units (CTUs). In accordance with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Guideline for Good Clinical Practice (GCP) and the European Union (EU) regulatory guidelines, one of the aims of the European Regime Accelerator for Tuberculosis (ERA4TB) project is to collaboratively create a feasibility tool, through a partnership between public and private entities, for the validation of CTUs selected to conduct FTIH trials. A feasibility form, encompassing nine sections, was created to gather information on the unit in relation to key attributes of FTIH trials. Collaboratively, industry and academic partners defined the minimal criteria to ensure the adherence of CTUs to the principles of ICH GCP and regulations outlined by the European Medicines Agency (EMA) for the execution of FTIH trials. Subsequently, all CTUs available for the project were assessed for FTIH trial eligibility. The introduction of the certification procedure through the feasibility tool within ERA4TB resulted in the accreditation of the five academic CTUs, which are now prepared to carry out FTIH trials as part of the Consortium. The developed feasibility tool aims to establish open and widely used minimum requirements for the validation of academic CTUs as FTIH units, marking it as the inaugural tool for CTU validation resulting from the collaboration between industry and academia within the ERA4TB project. The established partnership has enabled an innovative and novel way of working.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Published in:	Clinical and Translational Science, Vol. 16 Núm. 12 (december 2023) , p. 2421-2428, ISSN 1752-8062

DOI: 10.1111/cts.13655
PMID: 37818923

8 p, 551.6 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles